Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening
Shots: The approval is based on P-III ARCHER 1050 study assessing Vizimpro 45mg vs Gefitinib 250mg in a ratio (1:1) in patients with unresectable, mNSCLC harboring EGFR, exon 19 deletion or exon 21 L858R substitution mutations, with no prior therapy for metastatic disease or recurrent disease with a minimum of 12 mos. disease-free after completion […]Read More
